Previous 10 | Next 10 |
Shares of Arcus Biosciences Inc. (NYSE:RCUS) traded at a new 52-week high today of $48.26. Approximately 407,000 shares have changed hands today, as compared to an average 30-day volume of 546,000 shares. In the past 52 weeks, shares of Arcus Biosciences Inc. have traded between a low of...
Arcus Biosciences Inc. (NYSE:RCUS) traded at a new 52-week high today of $47.07. This new high was reached on below average trading volume as 348,000 shares traded hands, while the average 30-day volume is approximately 503,000 shares. Arcus Biosciences Inc is a clinical-stage biopharmac...
SVB Leerink is reiterating its outperform rating and raising its price target on Arcus Biosciences (RCUS +15.3%) to $100 from $68 (~171% upside) following Gilead's (GILD +1.1%) decision to exercise options on three programs. Analyst Geoffrey Porges says that the decision came sooner than expe...
Arcus Biosciences Inc. (NYSE:RCUS) traded today at a new 52-week high of $43.56. Approximately 924,000 shares have changed hands today, as compared to an average 30-day volume of 373,000 shares. In the past 52 weeks, shares of Arcus Biosciences Inc. have traded between a low of $22.28 an...
Shares of Arcus Biosciences (NYSE: RCUS) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead Sciences (NASDAQ: GILD) has decided to exercise its options for Arcus' two anti-TI...
-- Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) -- -- Arcus to Receive Option Payments Totaling $725 million -- -...
-- Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) -- -- Arcus to Receive Option Payments Totaling $725 million -- G...
Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer (NSCLC) Gilead Sciences has initiate...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, today announced that the company will report its financial results and a corporate update for the third...
BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...